PDC

Across TCGA pan-cancer cohorts, PDC mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PDC data layer compared with 27 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PDC mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PDC expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

LUAD, CCRCC, and UCEC are the cancer types where PDC mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	All	1.000	0.474	<.001	65	view →
CCRCC	OS	Median	All	0.962	0.667	.006	16	view →
UCEC	OS	Median	II,III,IV	1.000	0.346	.010	12	view →
HNSC	DFS	Tertile	III,IV	0.751	0.380	.017	11	view →
PDAC	DFS	Tertile	III,IV	0.834	0.202	.024	7	view →
GBM	OS	Tertile	All	0.697	0.341	.032	5	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PDC–LUAD (OS)

Open the LUAD breakdown →